PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Hyungsoo Kim, Hyungsoo Kim, Heejung Kim, Heejung Kim, Yongmei Feng, Yan Li, Hironari Tamiya, Stefania Tocci, Ze’ev A. Ronai
Abstract
correlated with prolonged survival of patients with melanoma. Combination of pharmacological (GSK3326595) or genetic (shRNA) inhibition of PRMT5 with immune checkpoint therapy limited growth of murine melanoma tumors (B16F10 and YUMM1.7) and enhanced therapeutic efficacy, compared with the effect of either treatment alone. Overall, our findings provide a rationale to test PRMT5 inhibitors in immunotherapy-based clinical trials as a means to enhance an antitumor immune response.
Topics & Concepts
MelanomaImmunotherapyImmunityStingInflammationCancer researchMedicineImmunologyAntigen presentationImmune systemT cellEngineeringAerospace engineeringCancer-related gene regulationinterferon and immune responsesImmune Cell Function and Interaction